Appendix A – Technology Specific Terms and Conditions Appendix B – Diligence Report Appendix C – Form of Royalty ReportExclusive License Agreement • June 28th, 2013 • Omni Bio Pharmaceutical, Inc. • Biological products, (no disgnostic substances) • Colorado
This Exclusive License Agreement (the “Agreement”) between the Regents of the University of Colorado, a body corporate, having its principal office at 1800 Grant Street, 8th Floor, Denver, CO 80203 (hereinafter “University”) and Omni Bio Pharmaceutical, Inc., a Colorado corporation, having its principal office at 5350 S. Roslyn Street, Suite 430, Greenwood Village, CO 80111 (hereinafter “Licensee”) is effective on the 18th of February, 2013, (the “Effective Date”).
AMENDMENT TWO TO SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • June 28th, 2013 • Omni Bio Pharmaceutical, Inc. • Biological products, (no disgnostic substances)
This Amendment made this 31st day of December, 2012 by and between the THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate, contracting for and on behalf of the University of Colorado Denver, a public institution of higher education created under the Constitution and the Law of the State of Colorado (hereinafter referred to as “UNIVERSITY”) and Omni Bio Pharmaceutical, Inc. hereinafter referred to as “Sponsor”.
